-
EP4333879
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4333879
| EP4333879 - VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 09.02.2024 Database last updated on 11.05.2024 | |
| Former | The international publication has been made Status updated on 11.11.2022 | ||
| Former | unknown Status updated on 20.05.2022 | Most recent event Tooltip | 01.05.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Pfizer Inc. 66 Hudson Boulevard East New York, NY 10001-2192 / US | [2024/11] | Inventor(s) | 01 /
ANDERSON, Annaliesa Sybil Pearl River, New York 10965 / US | 02 /
CANE, Alejandro David Collegeville, Pennsylvania 19426 / US | 03 /
GRUBER, William Carl Pearl River, New York 10965 / US | 04 /
JANSEN, Kathrin Ute Pearl River, New York 10965 / US | 05 /
JODAR MARTIN-MONTALVO, Luis Pascual Collegeville, Pennsylvania 19426 / US | 06 /
LOCKHART, Stephen Paul Sandwich Kent CT13 9NJ / GB | 07 /
SCOTT, Daniel Alfred Collegeville, Pennsylvania 19426 / US | 08 /
WATSON, Wendy Jo Collegeville, Pennsylvania 19426 / US | 09 /
YACISIN, Kari Ann Collegeville, Pennsylvania 19426 / US | [2024/11] | Representative(s) | Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | [2024/11] | Application number, filing date | 22722569.5 | 28.04.2022 | [2024/11] | WO2022IB53951 | Priority number, date | US202163183254P | 03.05.2021 Original published format: US 202163183254 P | US202163183630P | 03.05.2021 Original published format: US 202163183630 P | US202263325126P | 29.03.2022 Original published format: US 202263325126 P | [2024/11] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022234405 | Date: | 10.11.2022 | Language: | EN | [2022/45] | Type: | A1 Application with search report | No.: | EP4333879 | Date: | 13.03.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.11.2022 takes the place of the publication of the European patent application. | [2024/11] | Search report(s) | International search report - published on: | EP | 10.11.2022 | Classification | IPC: | A61K39/09, A61K39/116, A61K39/12, A61K39/295, A61K39/385, A61P31/04, A61P31/14 | [2024/11] | CPC: |
A61K39/12 (EP);
A61K39/092 (EP);
A61K39/116 (EP);
A61K39/295 (EP);
A61K39/385 (EP);
A61P31/04 (EP);
A61P31/14 (EP);
A61K2039/53 (EP);
A61K2039/55 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/11] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | IMPFUNG GEGEN BAKTERIELLE UND BETACORONAVIRUS-INFEKTIONEN | [2024/11] | English: | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | [2024/11] | French: | VACCINATION CONTRE DES INFECTIONS BACTÉRIENNES ET À BETACORONAVIRUS | [2024/11] | Entry into regional phase | 04.12.2023 | National basic fee paid | 04.12.2023 | Designation fee(s) paid | 04.12.2023 | Examination fee paid | Examination procedure | 09.11.2023 | Amendment by applicant (claims and/or description) | 04.12.2023 | Examination requested [2024/11] | 04.12.2023 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 30.04.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y] - MAHASE ELISABETH, "Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows", BMJ, (20201211), doi:10.1136/bmj.m4826, page m4826, XP055945868 [Y] 1-34 * the whole document * DOI: http://dx.doi.org/10.1136/bmj.m4826 | [Y] - JIA QINGMEI ET AL, "Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters", NPJ VACCINES, vol. 6, no. 1, doi:10.1038/s41541-021-00321-8, (20210330), URL: https://www.nature.com/articles/s41541-021-00321-8.pdf, XP055945470 [Y] 1-34 * abstract * DOI: http://dx.doi.org/10.1038/s41541-021-00321-8 | [Y] - MAEDA DENICAR LINA NASCIMENTO FABRIS ET AL, "Killed whole-genome reduced-bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a porcine model", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20210415), vol. 118, no. 18, doi:10.1073/pnas.2025622118, ISSN 0027-8424, XP055945476 [Y] 1-34 * abstract * DOI: http://dx.doi.org/10.1073/pnas.2025622118 | [Y] - LI ET AL, "A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice", VIRUSES, (20190829), vol. 11, no. 9, doi:10.3390/v11090799, page 799, XP055945474 [Y] 1-34 * abstract * DOI: http://dx.doi.org/10.3390/v11090799 | [IP] - Anonymous, "Promising results for COVID-19 and pneumococcal vaccine co-administration", European Phamaceutical Review, (20220114), URL: https://www.europeanpharmaceuticalreview.com/news/167524/promising-results-for-covid-19-and-pneumococcal-vaccine-co-administration/, (20220714), XP055942901 [IP] 1-34 * the whole document * | [A] - THOMPSON ALLISON ET AL, "Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 37, no. 42, doi:10.1016/J.VACCINE.2019.08.048, ISSN 0264-410X, (20190905), pages 6201 - 6207, (20190905), XP085812414 [A] 1 * abstract * DOI: http://dx.doi.org/10.1016/j.vaccine.2019.08.048 | [A] - Chaparian Ryan R. ET AL, "Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccine", bioRxiv, doi:10.1101/2021.04.30.441968, (20210430), URL: https://www.biorxiv.org/content/10.1101/2021.04.30.441968v1.full.pdf, (20220722), XP055945489 [A] 1 * Abstract; page 20 (vaccination of mice) * DOI: http://dx.doi.org/10.1101/2021.04.30.441968 | [A] - LEWNARD JOSEPH A ET AL, "Prevention of Coronavirus Disease 2019 Among Older Adults Receiving Pneumococcal Conjugate Vaccine Suggests Interactions Between Streptococcus pneumoniae and Severe Acute Respiratory Syndrome Coronavirus 2 in the Respiratory Tract", JOURNAL OF INFECTIOUS DISEASES, US, vol. 225, no. 10, doi:10.1093/infdis/jiab128, ISSN 0022-1899, (20210309), pages 1710 - 1720, URL: https://watermark.silverchair.com/jiab128.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAtswggLXBgkqhkiG9w0BBwagggLIMIICxAIBADCCAr0GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMSL6QUgRjrCNPwwLrAgEQgIICjsEuaIbtnmmrf22p1YrdNapSW9gNzwtiLffRSlykXNfecwpuvgrZZsd6tqCOgHj3lK9UE0JVV2biG6lYIkEWA5UrBIz2, XP055942775 [A] 1 * abstract * DOI: http://dx.doi.org/10.1093/infdis/jiab128 | by applicant | US4709017 | EP0372501 | EP0378881 | US4950740 | WO9101146 | EP0427347 | EP0471177 | WO9317712 | WO9403208 | EP0594610 | US5614382 | US5843711 | WO9858668 | US5917017 | WO0037105 | WO0039299 | WO0056357 | WO0061761 | WO0172337 | WO0198334 | US6455673 | WO02091998 | WO03054007 | WO2004081515 | WO2004083251 | WO2005033148 | WO2006032499 | US2006228380 | US2006228381 | WO2006110381 | WO2006110352 | US2007184072 | US2007184071 | US2007231340 | US2008102498 | WO2008079653 | WO2008118752 | US2008286838 | WO2008143709 | WO2009000826 | WO2010125480 | US8519110 | CN103495161 | WO2014027302 | WO2014097099 | US9950058 | US10821171 | - KORE et al., Bioorganic & Medicinal Chemistry, (20130000), vol. 21, pages 4570 - 4574 | - VOGEL AB et al., Nature, (20210400), vol. 592, no. 7853, pages 283 - 289 | - GAEBLER CNUSSENZWEIG MC, Nature, (20201000), vol. 586, no. 7830, pages 501 - 593 | - WALSH EE et al., The New England Journal of Medicine, (20201000), vol. 383, no. 25, page 2439 | - PALLESEN J et al., PNAS, (20170800), vol. 114, no. 35, pages E7348 - E7357 | - LEMERCINIER et al., Carbohydrate Research, (19960000), vol. 296, pages 83 - 96 | - JONES et al., J. Pharmaceutical and Biomedical Analysis, (20020000), vol. 30, pages 1233 - 1247 | - HESTRIN, J. Biol. Chem., (19490000), vol. 180, pages 249 - 261 | - UCHIDA et al., J. Biol. Chem., (19730000), vol. 218, pages 3838 - 3844 | - KUO et al., Infect Immun, (19950000), vol. 63, pages 2706 - 2713 | - FALUGI et al., Eur J Immunol, (20010000), vol. 31, pages 3816 - 3824 | - BARALDOI et al., Infect Immun, (20040000), vol. 72, pages 4884 - 4887 | - DOUGLAS et al., J. Bacteriol., (19870000), vol. 169, no. 11, pages 4967 - 4971 | - UCHIDA et al., Nature New Biology, (19710000), vol. 233, pages 8 - 11 | - "GenBank", Database accession no. 138250 | - "Swiss Prot", Database accession no. P13843 | - "GenBan", Database accession no. 138250 | - N Engl J Med, (20201231), vol. 383, no. 27, pages 2603 - 2615 |